Impact of IMP3 Expression on Chemotherapy Response and Prognosis in Triple-Negative Breast Cancer: A Retrospective Cohort Study

• DOI: 10.1272/jnms.jnms.2025_92-109
• Publication Date: 2025-03-06T22:13:33Z
• Authors: Mio Yagi; Koji Nagata; Megumi Sano; Keiko Yanagihara; Ryuji Ohashi; Hiroyuki Takei
• Keywords: Triple-negative breast cancer; Regimen

Although advances in neoadjuvant chemotherapy (NAC) are improving the rate of pathological complete response (pCR) and outcomes for triple-negative breast cancer (TNBC) patients, prognosis remains poor. Insulin-like growth factor II mRNA-binding protein 3 (IMP3) expression was recently reported to be associated with resistance poor TNBC. We evaluated IMP3 40 female TNBC patients assess its association NAC sensitivity outcome. Among cohort, 11 (27.5%) had IMP3-positive TNBC, which a higher Ki-67 labeling index (p = 0.119), indicating greater malignancy. However, positivity showed no significant correlation or differences disease-free survival (DFS) as compared IMP3-negative patients. Patients receiving effective immunotherapy high-dose achieved pCR regardless status, suggests that regimen is more important than status pCR. Even may improve by achieving Thus, while might predict prognosis, it not serve definitive marker context NAC. Because involved stem cell (CSC) function, further research necessary understand complex role CSCs